Ticker LaunchIPO · NVCT
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. (NVCT) priced its initial public offering on Feb 7, 2022 at $5.00 per share, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $63.6M. H.C. Wainwright was lead-left underwriter. Alston & Bird advised the company and Mintz advised the underwriters.
Nuvectis Pharma, Inc. is a biopharmaceutical company developing precision medicines for serious unmet needs in oncology. It builds a pipeline of targeted anticancer drugs using its skills in target selection, drug profiling, and clinical and regulatory execution.
- Status
- IPO
- Ticker
- NVCT
- Exchange
- Nasdaq Capital Market
- Priced
- Feb 7, 2022
- IPO price
- $5.00
- Market cap at IPO price
- $63.6M
- First filed
- Oct 6, 2021
- Underwriters
- H.C. Wainwright
- Company counsel
- Alston & Bird
- Underwriters' counsel
- Mintz
- Sector
- Biotech & pharma
- Country / state
- NJ
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Oct 6, 2021
- Latest amendment Jan 24, 2022
- Final prospectus (424B4) Feb 7, 2022
- All filings on EDGAR CIK 1875558
Other Biotech & pharma IPOs in 2022
- Onconetix, Inc.BWV · Feb 23, 2022 · $20M
- Smart for Life, Inc.SMFL · Feb 17, 2022 · $14.4M
- TC BioPharm (Holdings) plcTCBP · Feb 14, 2022
- Arcellx, Inc.ACLX · Feb 7, 2022 · $123.8M
- Amylyx Pharmaceuticals, Inc.AMLX · Jan 10, 2022 · $190M
- Vigil Neuroscience, Inc.VIGL · Jan 10, 2022 · $98M